Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5435_Библиотеки_им_академика_М_И_Перельмана
.pdf
density, which makes it easier to spot objects like atoms, molecules, and solvent areas.
Twinned crystals, modulated structu res, and disorder are only a few of the unique
crystallographic scenarios that may be handled with JANA2006’s characteristics. It of-
fers resources, including algorithms and tools made expressly to deal with these diffi-
cult crystallographic situations [125].
(xv) J-ICE: A user-friendly software program called J-ICE (Joint Industrial XRD and ele-
mental mapping software) is intended for the visualization and interpretation of XRD
data in the area of crystallography. It offers a variety of tools to make the interpreta-
tion and comprehension of crystal structures easier. Three-dimensional crystal struc-
ture visualization is possible with J-ICE. It offers interactive tools for examining
atomic coordinates, unit cells, crystal symmetry components, and other structural
characteristics. The structure may be moved about, zoomed in/on, and rotated to ex-
plore various viewpoints [126].
There are also some other tools or software available that are used for molecular vi-
sualization and other purposes in X-ray crystallography like XtalOpt, XtalPred, Xtal-
PiMS,XtalComp,XtalPlan,XtalTwin,XtalSystem, XtalDB, ShelXle, and Xta l2SHELX
[127, 128]
7.4 Conclusion
X-ray crystallography is an essential tool in CADD, which provides thorough details
regarding the three-dimensional structure of target proteins and their interactions
with small molecules. For the purpose of drug design, a number of molecular recog-
nizable tools are available for visualizing and analyzing crystal structures. With the
use of these techniques, researchers may learn more about the interactions, confor-
mational changes, and binding mechanisms of ligands inside the protein binding site.
Future attempts to identify new drugs and targets have a great deal to gain from fur-
ther improvements in these techniques.
References
[1] Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht,
A. L. How to improve R&D productivity: The pharmaceutical industry’s grand challenge. Nature
Reviews Drug Discovery, 2010, 9, 203–214.
[2] Song, C. M., Lim, S. J., & Tong, J. C. Recent advances in computer-aided drug design. Briefings in
Bioinformatics, 2009, 10, 579–591.
[3] DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. The price of innovation: New estimates of drug
development costs. Journal of Health Economics, 2003, 22, 151–185.
144 Vipul Kumar et al.
https://t.me/med1917
[4] Lavecchia, A., & Di Giovanni, C. Virtual screening strategies in drug discovery: A critical review.
Current Medicinal Chemistry, 2013, 20, 2839–2860.
[5] Jhoti, H., Rees, S., & Solari, R. High-throughput screening and structure-based approaches to hit
discovery: Is there a clear winner?. Expert Opinion on Drug Discovery, 2013, 8, 1449–1453.
[6] Ou-Yang, S., Lu, J., Kong, X., Liang, Z., Luo, C., & Jiang, H. Computational drug discovery. Acta
Pharmaceutica Sinica, 2012, 33, 1131–1140.
[7] Usha, T., Shanmugarajan, D., Goyal, A. K., Kumar, C. S., & Middha, S. K. Recent updates on
computer-aided drug discovery: Time for a paradigm shift. Current Topics in Medicinal Chemistry,
2018, 17, 3296–3307.
[8] Kapetanovic, I. M. Computer-aided drug discovery and development (CADDD): In silico-chemico-
biological approach. Chemico-Biological Interactions, 2008, 171, 165–176.
[9] Prieto-Martínez, F. D., López-López, E., Juárez-Mercado, K. E., Medina-Franco, J. L., Computational
drug design methods—current and future perspectives. In silico drug design, 2019, 19–44.
[10] Wang, Y. L., Wang, F., Shi, X. X., Jia, C. Y., Wu, F. X., Hao, G. F., & Yang, G. F. Cloud 3D-QSAR: A web
tool for the development of quantitative structure–activity relationship models in drug discovery.
Briefings in Bioinformatics, 2021, 22, doi:10.1093/bib/bbaa276.
[11] Giordano, D., Biancaniello, C., Argenio, M. A., & Facchiano, A. Drug design by pharmacophore and
virtual screening approach. Pharmaceuticals, 2022, 15, 646.
[12] Achary, P. G. R. Applications of quantitative structure-activity relationships (QSAR) based virtual
screening in drug design: A review. Mini-Reviews in Medicinal Chemistry, 2020, 20, 1375–1388.
[13] Sabe, V. T., Ntombela, T., Jhamba, L. A., Maguire, G. E. M., Govender, T., Naicker, T., & Kruger,
H. G. Current trends in computer aided drug design and a highlight of drugs discovered via
computational techniques: A review. European Journal of Medicinal Chemistry, 2021, 224, 113705.
[14] Cramer, R. D., Patterson, D. E., & Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect
of shape on binding of steroids to carrier proteins. Journal of the American Chemical Society, 1988,
110, 5959–5967.
[15] Zhang, Y. J. In silico technologies in drug design, discovery and development. Current Topics in
Medicinal Chemistry, 2010, 10, 617–618.
[16] Oprea, T. I., & Gottfries, J. Chemography: The art of navigating in chemical space. Journal of
Computational Chemistry, 2001, 3, 157–166.
[17] Gurung, A. B., Ali, M. A., Lee, J., Farah, M. A., Al-Anazi, K. M., An Updated Review of Computer-Aided
Drug Design and Its Application to COVID-19. Biomed Res Int, 2021, 2021, 8853056.
[18] Song, C. M., Lim, S. J., & Tong, J. C. Recent advances in computer-aided drug design. Briefings in
Bioinformatics, 2009, 10, 579–591.
[19] Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., &
Bourne, P. E. The protein data bank. Nucleic Acids Research, 2000, 28, 235 – 242.
[20] Leach, A. R., Shoichet, B. K., & Peishoff, C. E. Prediction of protein-ligand interactions. Docking and
scoring: Successes and gaps. Journal of Medicinal Chemistry, 2006, 49, 5851–5855.
[21] Hann, M. M. Molecular obesity, potency and other addictions in drug discovery. Medchemcomm,
2011, 2, 349–355.
[22] Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. Docking and scoring in virtual screening for
drug discovery: Methods and applications. Nature Reviews Drug Discovery, 2004, 3, 935–949.
[23] Reddy, A. S., Pati, S. P., Kumar, P. P., Pradeep, H. N., & Sastry, G. N. Virtual screening in drug
discovery – A computational perspective. Current Protein & Peptide Science, 2007, 8, 329–351.
[24] Hert, J., Willett, P., Wilton, D. J., Acklin, P., Azzaoui, K., Jacoby, E., & Schuffenhauer, A. Comparison of
topological descriptors for similarity-based virtual screening using multiple bioactive reference
structures. Organic and Biomolecular Chemistry, 2004, 2, 3256.
[25] Kapetanovic, I. M. Computer-aided drug discovery and development (CADDD): In silico-chemico-
biological approach. Chemico-Biological Interactions, 2008, 171, 165–176.
7 Molecular recognizable tools in X-ray crystallography in computer-aided drug design 145
https://t.me/med1917
[26] Koutsoukas, A., Simms, B., Kirchmair, J., Bond, P. J., Whitmore, A. V., Zimmer, S., Young, M. P.,
Jenkins, J. L., Glick, M., Glen, R. C., & Bender, A. From in silico target prediction to multi-target drug
design: Current databases, methods and applications. Journal of Proteomics, 2011, 74, 2554–2574.
[27] Daina, A., Michielin, O., & Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics,
drug-likeness and medicinal chemistryfriendliness of small molecules. Scientific Reports, 2017, 7, 42717.
[28] Ekins, S., & Freundlich, J. S. Validating new tuberculosis computational models with public whole cell
screening aerobic activity datasets. Pharmaceutical Research, 2011, 28, 1859–1869.
[29] Cheng, F., Li, W., Liu, G., & Tang, Y. In silico ADMET prediction: Recent advances, current challenges
and future trends. Current Topics in Medicinal Chemistry, 2013, 13, 1273–1289.
[30] Hu, Q., Feng, M., Lai, L., & Pei, J. Prediction of drug-likeness using deep autoencoder neural
networks. Frontiers in Genetics, 2018, 9, doi:10.3389/fgene.2018.00585.
[31] Yang, H., Sun, L., Li, W., Liu, G., & Tang, Y. In silico prediction of chemical toxicity for drug design
using machine learning methods and structural alerts. Frontiers in Chemistry, 2018, 6, doi:10.3389/
fchem.2018.00030.
[32] Rajkishan, T., Rachana, A., Shruti, S., Bhumi, P., & Patel, D. Advances in Bioinformatics. 2021,
(pp. 151–182). Springer Singapore: Singapore.
[33] Yu, W., Weber, D. J., MacKerell, A. D., Integrated Covalent Drug Design Workflow Using Site
Identification by Ligand Competitive Saturation. J Chem Theory Comput,. 2023, 19, 3007–3021.
[34] Yu, W., MacKerell, A. D., in: Sass, P. (Ed.), Antibiotics: Methods and Protocols. Springer New York,
New York, NY 2017, pp. 85–106.
[35] Waszkowycz, B., Perkins, T. D. J., Sykes, R. A., & Li, J. Large-scale virtual screening for discovering
leads in the postgenomic era. IBM Systems Journal, 2001, 40, 360–376.
[36] Chen, L. K., Morrow, J. T., Tran, H. S., Phatak, S., Du-Cuny, L., & Zhang, S. From laptop to benchtop to
bedside: Structure-based drug design on protein targets. Current Pharmaceutical Design, 2012, 18,
1217–1239.
[37] Lin, X., Li, X., & Lin, X. A review on applications of computational methods in drug screening and
design. Molecules, 2020, 25, 1375.
[38] Moreira, I. S., Fernandes, P. A., Ramos, M. J., Protein– protein docking dealing with the unknown. J
Comput Chem, 2010, 31, 317–342.
[39] Scapin, G. Structural biology and drug discovery. Current Pharmaceutical Design, 2006, 12,
2087–2097.
[40] Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. Artificial intelligence to
deep learning: Machine intelligence approach for drug discovery. Molecular Diversity, 2021, 25,
1315–1360.
[41] Mohan, V., Gibbs, A., Cummings, M., Jaeger, E., & DesJarlais, R. Docking: Successes and Challenges.
Current Pharmaceutical Design, 2005, 11, 323–333.
[42] Grant, M. Protein structure prediction in structure-based ligand design and virtual screening.
Combinatorial Chemistry & High Throughput Screening, 2009, 12, 940–960.
[43] Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. Docking and scoring in virtual screening for
drug discovery: Methods and applications. Nature Reviews Drug Discovery, 2004, 3, 935–949.
[44] Clark, D. E. What has computer-aided molecular design ever done for drug discovery?. Expert
Opinion on Drug Discovery, 2006, 1, 103–110.
[45] Talele, T., Khedkar, S., & Rigby, A. Successful applications of computer aided drug discovery: Moving
drugs from concept to the clinic. Current Topics in Medicinal Chemistry, 2010, 10, 127–141.
[46] Hanson, S. M., Newstead, S., Swartz, K. J., & Sansom, M. S. P. Capsaicin interaction with TRPV1
channels in a lipid bilayer: Molecular dynamics simulation. Biophysical Journal, 2015, 108,
1425–1434.
[47] Wang, Y., Shaikh, S. A., & Tajkhorshid, E. Exploring transmembrane diffusion pathways with
molecular dynamics. Physiology, 2010, 25, 142–154.
146 Vipul Kumar et al.
https://t.me/med1917
[48] Deb, P. K., Chandrasekaran, B., Mailavaram, R., Tekade, R. K., & Jaber, A. M. Y. Molecular modeling
approaches for the discovery of adenosine A2B receptor antagonists: Current status and future
perspectives. Drug Discovery Today, 2019, 24, 1854–1864.
[49] Shukla, R., & Tripathi, T. Innovations and Implementations of Computer Aided Drug Discovery
Strategies in Rational Drug Design. 2021, (pp. 295–316). Springer Singapore: Singapore.
[50] Verma, J., Khedkar, V., & Coutinho, E. 3D-QSAR in drug design – A review. Current Topics in
Medicinal Chemistry, 2010, 10, 95–115.
[51] Yang, S. Y. Pharmacophore modeling and applications in drug discovery: Challenges and recent
advances. Drug Discovery Today, 2010, 15, 444–450.
[52] Acharya, C., Coop, A. E., Polli, J. D., & MacKerell, A. Recent advances in ligand-based drug design:
Relevance and utility of the conformationally sampled pharmacophore approach. Current Computer
Aided-Drug Design, 2011, 7, 10–22.
[53] Mason, J., Good, A., & Martin, E. 3-D pharmacophores in drug discovery. Current Pharmaceutical
Design, 2001, 7, 567–597.
[54] Loew, G. H., Villar, H. O., & Alkorta, I. Strategies for indirect computer-aided drug design.
Pharmaceutical Research, 1993, 10, 475–486.
[55] Blundell, T. L., & Patel, S. High-throughput X-ray crystallography for drug discovery. Current
Opinion in Pharmacology, 2004, 4, 490–496.
[56] Badger, J., in: Tari, L. W. (Ed.), Structure-Based Drug Discovery. Humana Press, Totowa, NJ, 2012, pp.
161–177.
[57] Smyth, M. S., & Martin, J. H., x ray crystallography. Molecular Pathology, 2000, 53, 8–14.
[58] Souza, D. H. F., Selistre-de-araujo, H. S., & Garratt, R. C. Determination of the three-dimensional
structure of toxins by protein crystallography. Toxicon, 2000, 38, 1307–1353.
[59] Xu, Q., & Dunbrack, R. L. Principles and characteristics of biological assemblies in experimentally
determined protein structures. Current Opinion in Structural Biology, 2019, 55, 34–49.
[60] Robertus, J. Principles of protein X-Ray crystallography, 3rd Edition by Jan Drenth (University of
Groningen, The Netherlands). with a major contribution from Jeroen Mester (University of Lübeck,
Germany). Springer Science + Business Media LLC: New York. 2007. xiv + 332 pp. $89.95.
ISBN 0-387-33334-7. Journal of the American Chemical Society, 2007, 129, 5782–5783.
[61] Ealick, S. E. Principles of protein X-ray crystallography by J. Drenth. Acta Crystallographica Section
D: Biological Crystallography, 1995, 51, 248–248.
[62] Hickman, A. B., & Davies, D. R. Principles of macromolecular X‐Ray crystallography. Current
Protocols in Protein Science, 1997, 10, doi:10.1002/0471140864.ps1703s10.
[63] Stock, D., Perisic, O., & Löwe, J. Robotic nanolitre protein crystallisation at the MRC laboratory of
molecular biology. Progress in Biophysics and Molecular Biology, 2005, 88, 311–327.
[64] Maveyraud, L., & Mourey, L. Protein X-ray crystallography and drug discovery. Molecules, 2020,
25, 1030.
[65] Huxford, T., Brenner’s Encyclopedia of Genetics. Academic Press, 2013, pp. 366–368.
[66] Rhodes, G., Cooper, J. B., Crystallography Made Crystal Clear. Trends Biotechnol, 1994, 12, 142.
[67] Pal, S., Mathematical Approaches to Molecular Structural Biology. Elsevier, 2023, pp. 211–233.
[68] Nachiappan, M., Guru Raj Rao, R., Richard, M., Prabhu, D., Rajamanikandan, S., Chitra, J. P.,
Jeyakanthan, J., Molecular Docking for Computer-Aided Drug Design. Elsevier, 2021, pp. 119–140.
[69] Ejalonibu, M. A., Ogundare, S. A., Elrashedy, A. A., Ejalonibu, M. A., Lawal, M. M., Mhlongo, N. N., &
Kumalo, H. M. Drug discovery for mycobacterium tuberculosis using structure-based computer-
aided drug design approach. International Journal of Molecular Sciences, 2021, 22, 13259.
[70] Choudhury Chinmayee and Narahari Sastry, G., in: Mohan, C. G. (Ed.), Structural Bioinformatics:
Applications in Preclinical Drug Discovery Process. Springer International Publishing, Cham, 2019,
pp. 25–53.
7 Molecular recognizable tools in X-ray crystallography in computer-aided drug design 147
https://t.me/med1917
[71] Carabet, L., Rennie, P., & Cherkasov, A. Therapeutic Inhibition of Myc in Cancer. Structural Bases
and Computer-Aided Drug Discovery Approaches. International Journal of Molecular Sciences, 2018,
20, 120.
[72] Stanzione, F., Giangreco, I., Cole, J. C., Use of molecular docking computational tools in drug
discovery. Prog Med Chem, 2021, 60, 273–343.
[73] Lu, I. L., Huang, C. F., Peng, Y. H., Lin, Y. T., Hsieh, H. P., Chen, C. T., Lien, T. W., Lee, H. J., Mahindroo,
N., Prakash, E., Yueh, A., Chen, H. Y., Goparaju, C. M. V., Chen, X., Liao, C. C., Chao, Y. S., Hsu, J. T. A.,
& Wu, S. Y. Structure-based drug design of a novel family of PPARγ partial agonists: Virtual
screening, X-ray crystallography, and in vitro/in vivo biological activities. Journal of Medicinal
Chemistry, 2006, 49, 2703–2712.
[74] Ooms, F. Molecular modeling and computer aided drug design. Examples of their applications in
medicinal chemistry. Current Topics in Medicinal Chemistry, 2000, 7, 141–158.
[75] Davis, A. M., Teague, S. J., & Kleywegt, G. J. Application and limitations of X-ray crystallographic data
in structure-based ligand and drug design. Angewandte Chemie International Edition, 2003, 42,
2718–2736.
[76] Blundell, T. L., & Patel, S. High-throughput X-ray crystallography for drug discovery. Current
Opinion in Pharmacology, 2004, 4, 490–496.
[77] Davies Thomas G. and Tickle, I. J., in: Davies Thomas G. and Hyvönen, M. (Ed.), Fragment-Based
Drug Discovery and X-Ray Crystallography. Springer Berlin Heidelberg, Berlin, Heidelberg, 2012, pp.
33–59.
[78] Hennig Michael and Ruf, A. and H. W., in: Davies Thomas G. and Hyvönen, M. (Ed.), Fragment-Based
Drug Discovery and X-Ray Crystallography. Springer Berlin Heidelberg, Berlin, Heidelberg, 2012, pp.
115–143.
[79] Blundell, T. L., Jhoti, H., & Abell, C. High-throughput crystallography for lead discovery in drug
design. Nature Reviews Drug Discovery, 2002, 1, 45–54.
[80] Spek, A. L. checkCIF validation ALERTS: What they mean and how to respond. Acta Crystallogr E
Crystallogr Commun, 2020, 76, 1–11.
[81] Jiang, W., Baker, M. L., Ludtke, S. J., & Chiu, W. Bridging the information gap: Computational tools
for intermediate resolution structure interpretation. Journal of Molecular Biology, 2001, 308,
1033–1044.
[82] Kendrew, J. C. Myoglobin and the structure of proteins. Science, 1979, 1963 139, 1259–1266.
[83] Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. Improved methods for building protein
models in electron density maps and the location of errors in these models. Acta Crystallographica
Section A: Foundations of Crystallography, 1991, 47, 110–119.
[84] Wondratschek, H., & Müller, U. (eds) International Tables for Crystallography. 2006, International
Union of Crystallography: Chester, England.
[85] Engh, R. A., & Huber, R. Accurate bond and angle parameters for X-ray protein structure
refinement. Acta Crystallographica Section A: Foundations of Crystallography, 1991, 47, 392–400.
[86] Nangia, A. Database research in crystal engineering. CrystEngComm, 2002, 4, 93.
[87] Spek, A. L. Structure validation in chemical crystallography. Acta Crystallographica Section
D: Biological Crystallography, 2009, 65, 148–155.
[88] Nangia, A. Conformational polymorphism in organic crystals. Accounts of Chemical Research, 2008,
41, 595–604.
[89] Allen, F. H. The Cambridge structural database: A quarter of a million crystal structures and rising.
Acta Crystallographica Section B: Structural Science, 2002, 58, 380–388.
[90] Dunitz, J. D., & Gavezzotti, A. How molecules stick together in organic crystals: Weak intermolecular
interactions. Chemical Society Reviews, 2009, 38, 2622.
[91] Van Der Sluis, P., & Kroon, J. Solvents and x-ray crystallography. Journal of Crystal Growth, 1989, 97,
645–656.
148 Vipul Kumar et al.
https://t.me/med1917
[92] Schoenborn, B. P., Garcia, A., & Knott, R. Hydration in protein crystallography. Progress in
Biophysics and Molecular Biology, 1995, 64, 105–119.
[93] Bricogne, G., Vonrhein, C., Flensburg, C., Schiltz, M., & Paciorek, W. Generation, representation and
flow of phase information in structure determination: Recent developments in and around SHARP
2.0. Acta Crystallographica Section D: Biological Crystallography, 2003, 59, 2023–2030.
[94] Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. Improved methods for building protein
models in electron density maps and the location of errors in these models. Acta Crystallographica
Section A: Foundations of Crystallography, 1991, 47, 110–119.
[95] Sheldrick, G. M. A short history of SHELX. Acta Crystallographica Section A: Foundations of
Crystallography, 2008, 64, 112–122.
[96] Cooper, D. R., Porebski, P. J., Chruszcz, M., & Minor, W. X-ray crystallography: Assessment and
validation of protein–small molecule complexes for drug discovery. Expert Opinion on Drug
Discovery, 2011, 6, 771–782.
[97] Patel, H., Grüning, B. A., Günther, S., & Merfort, I. PyWATER: A PyMOL plug-in to find conserved
water molecules in proteins by clustering. Bioinformatics, 2014, 30, 2978–2980.
[98] Alexander, N., Woetzel, N., Meiler, J., 2011 IEEE 1st International Conference on Computational
Advances in Bio and Medical Sciences (ICCABS). IEEE, 2011, pp. 13–18.
[99] Ordog, R. PyDeT, a PyMOL plug-in for visualizing geometric concepts around proteins.
Bioinformation, 2008, 2, 346–347.
[100] Potterton, L., Agirre, J., Ballard, C., Cowtan, K., Dodson, E., Evans, P. R., Jenkins, H. T., Keegan, R.,
Krissinel, E., Stevenson, K., Lebedev, A., McNicholas, S. J., Nicholls, R. A., Noble, M., Pannu, N. S.,
Roth, C., Sheldrick, G., Skubak, P., Turkenburg, J., Uski, V., Von Delft, F., Waterman, D., Wilson, K.,
Winn, M., & Wojdyr, M. CCP 4 i 2: The new graphical user interface to the CCP 4 program suite. Acta
Crystallographica Section D: Biological Crystallography, 2018, 74, 68–84.
[101] Carvalho Ana Luísa and Trincão, J. and R. M. J., in: Roque, A. C. A. (Ed.), Ligand-Macromolecular
Interactions in Drug Discovery: Methods and Protocols. Humana Press, Totowa, NJ, 2010, pp. 31–56.
[102] Humphrey, W., Dalke, A., & Schulten, K. VMD: Visual molecular dynamics. Journal of Molecular
Graphics, 1996, 14, 33–38.
[103] Bond, P. S., Wilson, K. S., & Cowtan, K. D. Predicting protein model correctness in Coot using
machine learning. Acta Crystallographica Section D: Biological Crystallography, 2020, 76, 713–723.
[104] Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. Features and development of Coot. Acta
Crystallographica Section D: Biological Crystallography, 2010, 66, 486–501.
[105] Thomas, I. R., Bruno, I. J., Cole, J. C., Macrae, C. F., Pidcock, E., & Wood, P. A. WebCSD : The online
portal to the cambridge structural database. Journal of Applied Crystallography, 2010, 43, 362–366.
[106] Scalfani, V. F., Williams, A. J., Tkachenko, V., Karapetyan, K., Pshenichnov, A., Hanson, R. M., Liddie,
J. M., & Bara, J. E. Programmatic conversion of crystal structures into 3D printable files using Jmol.
Journal of Cheminformatics, 2016, 8, 66.
[107] Jmol: An open-source Java viewer for chemical structures in 3D, https://jmol.sourceforge.net/. (last
time accessed: May 23, 2023).
[108] Goddard, T. D., Huang, C. C., Meng, E. C., Pettersen, E. F., Couch, G. S., Morris, J. H., & Ferrin,
T. E. UCSF ChimeraX: Meeting modern challenges in visualization and analysis. Protein Science,
2018, 27, 14–25.
[109] Pettersen, E. F., Goddard, T. D., Huang, C. C., Meng, E. C., Couch, G. S., Croll, T. I., Morris, J. H., &
Ferrin, T. E. UCSF ChimeraX : Structure visualization for researchers, educators, and developers.
Protein Science, 2021, 30, 70–82.
[110] Rodenbough, P. P., Vanti, W. B., & Chan, S. W. 3D-printing crystallographic unit cells for learning
materials science and engineering. Journal of Chemical Education, 2015, 92, 1960–1962.
[111] Izumi, F., & Momma, K. Three-dimensional visualization in powder diffraction. Solid State
Phenomena, 2007, 130, 15–20.
7 Molecular recognizable tools in X-ray crystallography in computer-aided drug design 149
https://t.me/med1917
[112] VESTA (Visualisation for Electronic and Structural Study), https://jp-minerals.org/vesta/en/. (last
time accessed: May 23, 2023).
[113] Macrae, C. F., Sovago, I., Cottrell, S. J., Galek, P. T. A., McCabe, P., Pidcock, E., Platings, M., Shields,
G. P., Stevens, J. S., Towler, M., & Wood, P. A. Mercury 4.0 : From visualization to analysis, design
and prediction. Journal of Applied Crystallography, 2020, 53, 226–235.
[114] Xtaldraw, http://ccp14.cryst.bbk.ac.uk/ccp/web-mirrors/xtaldraw/crystal/. (last time accessed:
May 23, 2023).
[115] Moeck, P., Čertík, O., Upreti, G., Garrick, W., & Fraundorf, P. Crystal structure visualizations in three
dimensions with database support. MRS Proceedings, 2005, 909, 0909-PP03-05.
[116] Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung,
L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J.,
Richardson, D. C., Richardson, J. S., Terwilliger, T. C., & Zwart, P. H. PHENIX : A comprehensive
Python-based system for macromolecular structure solution. Acta Crystallographica Section
D: Biological Crystallography, 2010, 66, 213–221.
[117] Liebschner, D., Afonine, P. V., Baker, M. L., Bunkóczi, G., Chen, V. B., Croll, T. I., Hintze, B., Hung,
L. W., Jain, S., McCoy, A. J., Moriarty, N. W., Oeffner, R. D., Poon, B. K., Prisant, M. G., Read, R. J.,
Richardson, J. S., Richardson, D. C., Sammito, M. D., Sobolev, O. V., Stockwell, D. H., Terwilliger, T. C.,
Urzhumtsev, A. G., Videau, L. L., Williams, C. J., & Adams, P. D. Macromolecular structure
determination using X-rays, neutrons and electrons: Recent developments in Phenix. Acta
Crystallographica Section D: Biological Crystallography, 2019, 75, 861–877.
[118] Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Echols, N., Headd, J. J., Hung, L. W., Jain, S.,
Kapral, G. J., Grosse Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R. D., Read, R. J.,
Richardson, D. C., Richardson, J. S., Terwilliger, T. C., & Zwart, P. H. The Phenix software for
automated determination of macromolecular structures. Methods, 2011, 55, 94–106.
[119] Sheldrick, G. M. Macromolecular phasing with SHELXE. Zeitschrift Für Kristallographie – Crystalline
Materials, 2002, 217, 644–650.
[120] Sheldrick, G. M. A short history of SHELX. Acta Crystallographica Section A: Foundations and
Advances, 2008, 64, 112–122.
[121] Sheldrick, G. M. SHELXT – Integrated space-group and crystal-structure determination. Acta
Crystallographica Section A: Foundations and Advances, 2015, 71, 3–8.
[122] Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K., & Puschmann, H. OLEX2 : A complete
structure solution, refinement and analysis program. Journal of Applied Crystallography, 2009, 42,
339–341.
[123] Bergerhoff, G., Berndt, M., & Brandenburg, K. Evaluation of crystallographic data with the program
DIAMOND. Journal of Research of the National Institute of Standards and Technology, 1996,
101, 221.
[124] McRee, D. E. XtalView/Xfit – A versatile program for manipulating atomic coordinates and electron
density. Journal of Structural Biology, 1999, 125, 156–165.
[125] Palatinus, L., & Chapuis, G. SUPERFLIP – A computer program for the solution of crystal structures
by charge flipping in arbitrary dimensions. Journal of Applied Crystallography, 2007, 40, 786–790.
[126] Canepa, P., Hanson, R. M., Ugliengo, P., & Alfredsson, M. J-ICE : A new Jmol interface for handling
and visualizing crystallographic and electronic properties. Journal of Applied Crystallography, 2011,
44, 225–229.
[127] Hübschle, C. B., Sheldrick, G. M., & Dittrich, B. ShelXle : A Qt graphical user interface for SHELXL.
Journal of Applied Crystallography, 2011, 44, 1281–1284.
[128] Lonie, D. C., & Zurek, E. XtalOpt: An open-source evolutionary algorithm for crystal structure
prediction. Computer Physics Communications, 2011, 182, 372–387.
150 Vipul Kumar et al.
https://t.me/med1917
Disha Tewari, Priyanka Sharma, Shalini Mathpal, Kalpana Rawat,
Tushar Joshi, Subhash Chandra
✶
, and Veena Pande
8 Design of target hit molecules using
molecular dynamic simulations: special key
aspects of GROMACS or Role of molecular
dynamic simulations in designing a hit
molecule for drug discovery
Summary: The application of molecular dynamic (MD) simulations to design a hit
molecule has emerged as a powerful approach in drug discovery and computational
chemistry. In this study, we focus on the special key aspects of Gromacs, a widely
used MD simulation package, for designing target hit molecules.
We begin by discussing the fundamental principles of MD simulations and their
application in the field of drug discovery. MD simulations allow for the exploration of
molecular interactions and dynamic behavior at the atomic level, providing valuable
insights into the structural and functional properties of biomolecules.
Next, we delve into the key aspects of Gromacs that make it an ideal tool for de-
signing target hit molecules. Gromacs offers an extensive range of force fields, en-
abling accurate representation of molecular systems and interactions. Addition ally,
Gromacs provides advanced algorithms for efficient parallelization, enabling high-
performance simulations on modern computing architectures.
We explore various strategies and techniques within Gromacs that facilitate the
design of target hit molecules. This includes the use of enhanced sampling methods,
such as replica exchange MD and metadynamics, to overcome limitations associated
with exploring conformational space and sampling rare events. We also discuss the
incorporation of advanced free energy calculation methods, such as thermodynamic
integration and umbrella sampling, to estimate binding affinities and identify promis-
ing lead compounds.
Furthermore, we highlight the importance of accurate parameterization and valida-
tion of force fields in Gromacs to ensure reliable simulations and accurate predictions.
✶
Corresponding author: Subhash Chandra, Computational Biology and Biotechnology Laboratory,
Department of Botany, Soban Singh Jeena University, Almora, Uttarakhand, India
Disha Tewari, Shalini Mathpal, Tushar Joshi, Veena Pande, Department of Biotechnology,
Kumaun University, Bhimtal, Uttarakhand, India
Priyanka Sharma, Department of Botany, D.S.B. Campus, Kumaun University, Nainital, Uttarakhand,
India
Kalpana Rawat, Computational Biology and Biotechnology Laboratory, Department of Botany, Soban
Singh Jeena University, Almora, Uttarakhand, India
https://doi.org/10.1515/9783111207117-008
https://t.me/med1917
We discuss the use of empirical force fields, as well as the emerging field of quantum
mechanics/molecular mechanics (QM/MM) simulations, which combine the accuracy of
quantum mechanics with the efficiency of molecular mechanics.
Finally, in the present study, we design a target for COVID-19 as an example, where
Gromacs has been successfully applied in the design of target hit molecules. These exam-
ples demonstrate the potential of Gromacs as a valuable tool for rational drug design
and the discovery of novel therapeutics.
In conclusion, this study showcases the special key aspects of Gromacs in design-
ing target hit molecules using MD simulations. The capabilities of Gromacs, combined
with its user-friendly interface and extensive documentation, make it an essential
software package for researchers in the field of computational chemistry and drug
discovery.
Keywords: GROMACS, MD simulation, Drug Discovery, Hit molecules
8.1 Introduction
8.1.1 Molecular dynamic simulation
MD simulation was initially developed in the late 1970s [1, 2] and has since undergone
significant advancements. Initially, simulations were limited to simulating only a few
hundred atoms, but today, simulations of entire proteins in solution, large macromolec-
ular complexes [3, 4] such as ribosomes [5, 6], nucleosomes, and membrane-embedded
proteins are possible. However, with the availability of sufficient computing resources,
today’s simulations can routinely handle systems containing approximately 50,000–
100,000 atoms and even up to 500,000 atoms. These advancements have greatly ex-
panded the scope and applicability of MD simulations in studying various molecular
systems, enabling researchers to gain insights into the behavior and properties of com-
plex biological molecules and materials that would be challenging or impossible to
study experimentally. MD simulations utilize a fundamental model of interatomic inter-
actions to forecast the movements of all atoms in a molecular system, such as a protein,
throughout a given period. This enables the prediction of molecular behavior and struc-
tural changes under specific conditions [7]. These simulations, which display the posi-
tions of all the atoms at femtosecond temporal resolution, can capture a wide range of
crucial biomolecular processes such as conformational change, ligand binding, and pro-
tein folding. Numerous experimental structural biology methods are frequently com-
bined with MD simulations including cryoelectron mic roscopy (cryo-EM), nuclear
magnetic resonance (NMR), X-ray crystallog raphy, fast resonance energy transfer
(FRET), and electron paramagnetic resonance (EPR).
152 Disha Tewari et al.
https://t.me/med1917
8.1.2 Brief history
Simulation of biological molecules was a relatively obscure field until the 1950s, but
within a decade, it became a highly popular topic in research. In 1957–1959, Alder and
Wainwright first introduced molecular dynamic simulation as a tool for studying the
interactions of hard spheres. The first simulation results on a realistic model system
using molecular dynamic simulation were published by Rahman [8] in 1964, which
involved simulating liquid argon. Protein simulations were first demonstrated in 1977
through the simulation of the bovine pancreatic trypsin inhibitor. This marked a sig-
nificant milestone in the field of MD, as it provided insight into the behavior and func-
tion of proteins at a molecular level. The discovery of the villain protein’sfolding
mechanism by Duan and Kollman [9] using MD modeling in the 1990s is seen as a
turning point in this field.
8.1.3 Why we do a simulation (the basic idea behind simulation)
The basic idea behind the simulation is to mimic and study the behavior of a real-world
system or phenomenon by creating its virtual representation using a computer model.
Simulation allows us to understand and predict the dynamics, interactions, and out-
comes of complex systems that may be difficult or impractical to study directly.
The process of simulation involves breaking down the system into its constituent
parts and defining the rules, equations, or algorithms that govern their behavior.
These rules can be based on fundamental physical principles, empirical data, or a
combination of both. By applying these rules iteratively over time, the simulation
progresses and generates a sequence of states or events that reflect the evolution of
the system.
Simulation provides a means to explore different scenarios, test hypotheses, and
observe the system’s behavior under various conditions. It allows researchers to in-
vestigate the effects of different parameters, inputs, or interventions on the system’s
performance, dynamics, or outcomes.
Simulation is widely used in various fields, such as physics, engineering, biol-
ogy, social sciences, and computer science. It plays a crucial role in understanding
complex phenomena, optimizing designs, predicting outcomes, and making in-
formed decisions. Additionally, simulations can help bridge the gap between theory
and experimentation, providing insights and predictions that can gui de further re-
search or practical applications.
Overall, the basic idea behind a simulation is to create a virtual representation of
a system or process, apply rules or algorithms to simulate its behavior and use the
simulated results to gain insights, make predictions, or make informed decisions.
For many different causes, simulations are effective. Some of these are: (i) They re-
cord the position and mobility of each atom at every instant of time, which is extremely
8 Design of target hit molecules using molecular dynamic simulations 153
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана